New Analyst Forecast: $ONC Given $476 Price Target
Morgan Stanley analyst Sean Laaman set a $476 price target for ONC. 11 analysts have issued targets in the last 6 months, with a median of $446. ONC insiders sold 170 times in the past 6 months, and 196 institutional investors added shares while 115 decreased positions.
How this was made
The 30-second read
Why it matters
While the new $476 target is bullish, the extensive insider selling and fund outflows suggest mixed signals.
Market read
Primary new analyst target for ONC provides a fresh catalyst, but offset by insider and fund sell pressure.
What to watch
Heavy insider selling and recent hedge fund exits could temper the upside.
Background
The article aggregates recent analyst price targets, insider sales, and hedge‑fund activity for ONC.
Ticker impact
Morgan Stanley analyst Sean Laaman issued a new price target of $476 for ONC on 11/13/2026.
likely upward pressure as investors price in the higher target
Analyst price target upgrades often lead to short‑term buying interest, especially when the new target is substantially above recent levels.
Market effects
The upgrade may lift sentiment in the biotech sector as peers are re‑rated.
US biotech investors could see modest inflows.
Limited to investors tracking US biotech equities.
Counterpoint
Some investors may view the target as overly optimistic given recent insider sales.
Key entities
- analystSean Laaman
Morgan Stanley analyst who set the $476 target.
- insiderJohn Oyer
CEO of ONC who sold 918,376 shares.
